Panion’s epilepsy drug candidate shows positive initial results in a long-term study by CombiGene
Panion Animal Health AB develops a new epilepsy medicine for dogs based on CombiGene’s drug vector CG01. Initial results from CombiGene’s long-term study in rats was released yesterday in a message, which is highly relevant for Panion’s development of the product for epilepsy in dogs.
Professor Merab Kokaia from Lund University, who has lead the study, expresses his joy over the results.
He explains that the study analyses three different parameters related to the epileptic brain.
- Magnetic Resonance scanning (MR) evaluates the magnitude of damage in the brain;
- Electro-encephalography (Video-EEG) observes the epileptic attacks and measures the electric activity of the brain during a seizure;
- Histological analysis of the brain tissue that evaluates changes in the epileptic brain tissue compared to normal tissue and measures the expression of CG01 in the tissue.
This film presents the study:
https://vimeo.com/245921380 (English subtitles).
“We congratulate CombiGene with the excellent performance of this important in-vivo study, which confirms our trust in the scientific robustness of the future treatment” says Anja Holm, CEO of Panion.
Anja E. H. Holm, CEO
+ 45-22 94 66 00
Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.